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The epithelial-to-mesenchymal transition (EMT) is
important for the development of cancer metastases
and organ fibrosis, conditions prevalent in aging.
Because sirtuins affect the pathology of aging, we
tested the effect of SirT1 on EMT. Reduced SIRT1
levels in HMLER breast cancer cells led to increased
metastases in nude mice, and the loss of SIRT1 in
kidney tubular epithelial cells exacerbated injury-
induced kidney fibrosis. SIRT1 reduces EMT in
cancer and fibrosis by deacetylating Smad4 and re-
pressing the effect of TGF-b signaling on MMP7, a
Smad4 target gene. Consequently, less E-cadherin
is cleaved from the cell surface and b-catenin re-
mains bound to E-cadherin at the cell-cell junctions.
Our findings suggest that the SIRT1/Smad4/b-cate-
nin axis may be a target for diseases driven by EMT.INTRODUCTION
The epithelial-to-mesenchymal transition (EMT) is a process in
which epithelial cells lose cell-adhesive properties, repress
E-cadherin expression, and increase mesenchymal gene ex-
pression and cell mobility. It is essential for three distinct bio-
logical processes: embryogenesis, organ fibrosis, and cancer
metastases (Kalluri and Weinberg, 2009).
In cancer, EMT enables carcinoma cells to acquire cellular
traits associated with high-grade malignancy and metastasis
(Brabletz et al., 2005; Singh and Settleman, 2010). Some of the
epithelial cells that enter EMT acquire the properties of stem cells
(Mani et al., 2008; Morel et al., 2008). Importantly, this includes
the potential for self-renewal, which may facilitate the formation
of secondary tumors by disseminating cancer cells. EMT-
derived migratory cancer cells establish secondary colonies at
distant sites that resemble, at the histopathological level, the pri-
mary tumor from which they arose, suggesting that metasta-
sizing cancer cells shed their mesenchymal phenotype via a
mesenchymal to epithelial transition (MET) during the coloniza-
tion process (Kalluri and Weinberg, 2009; Yao et al., 2011).
EMT was also proposed to occur in fibrosis of kidney, liver,
heart, lung, and intestine (Potenta et al., 2008; Zeisberg et al.,
2007; Kim et al., 2006). However, recent studies raised seriousCdoubts about the existence of EMT in kidney fibrosis (Hum-
phreys et al., 2010; Li et al., 2010b).
EMT in cancer progression and organ fibrosis is associated
with aging (Mani et al., 2008; Chaturvedi and Hass, 2011;
Pannarale et al., 2010). Indeed, aging is one of the single most
important risk factors associated with cancer with nearly 65%
of cancers occurring in patients R65 years old (Ertel et al.,
2012). Similarly, fibrosis is a hallmark of pathogenesis associ-
ated with aging in many organs (Abrass et al., 1995).
Sirtuins are highly conserved nicotinamide-adenine-dinucleo-
tide -dependent deacetylases that were shown to regulate
lifespan in lower organisms (Tissenbaum and Guarente, 2001;
Viswanathan and Guarente, 2011) and affect diseases of aging
in mammals, such as diabetes, inflammation, and neurodegen-
erative diseases (Donmez and Guarente, 2010). The Sir2 ortho-
log SIRT1 is known to deacetylate transcription factors that
govern pathways important for aging and diseases (Imai et al.,
2000; Guarente, 2011).
Furthermore, calorie restriction protects against breast cancer
(Nogueira et al., 2012), as well as against fibrotic kidney failure
(Tapp et al., 1989) via SIRT1 (Kume et al., 2010). Indeed, there
is a strong link between sirtuins andmany of the effects of calorie
restriction (Lin et al., 2000; Guarente and Picard, 2005), hinting at
a possible relationship between mammalian SIRT1 and EMT.
The role of SIRT1 in cancer has been shown in several studies
to be cell type dependent and complex (see Discussion). Here,
we investigated the role of SIRT1 in EMT in cancer metastasis
and fibrosis. For this purpose, we analyzed themetastatic poten-
tial of breast cancer cells with or without SIRT1 after implantation
into nude mice. We also probed the role of SIRT1 in long-term
effects of ischemia reperfusion on kidney fibrosis in mice with
varying levels of SIRT1 expression in tubular epithelial cells. After
observing significant effects in these systems, we demonstrated
that SIRT1 restrains the transforming-growth-factor (TGF)-
b-signaling pathway, which is known to drive EMT. Our findings
cast light on links between sirtuins and disease states abetted by
the EMT.
RESULTS
Decrease in SIRT1 Level Promotes Breast Cancer
Metastases via EMT
We initially tested the effect of SIRT1 on EMT in breast cancer
cells. HMLER cells are primary human mammary epithelial cells
(HMECs), which express the telomerase catalytic subunit, SV40ell Reports 3, 1175–1186, April 25, 2013 ª2013 The Authors 1175
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large T and small t antigens (HMLE cells), and an oncogenic allele
of H-Ras, H-RasV12 (Elenbaas et al., 2001). These cells are
tumorigenic when injected subcutaneously or into the mammary
glands of immunocompromised mice but have very low meta-
static potential (Elenbaas et al., 2001, Ince et al., 2007). Treat-
ment of HMLER cells with TGF-b led to transition of epithelial
to mesenchymal cells as shown by a reduction of E-cadherin
(epithelial marker) and an increase in vimentin (mesenchymal
marker, Figure 1A). Overexpression of SIRT1 reduced EMT,
while repression of SIRT1 by small interfering RNA (siRNA)
increased EMT of HMLER cells in these assays (Figures 1A
and S1A). Similar albeit less dramatic results were repeated in
another breast cancer line MDA-MB231 (Figure S1B).
HMLER cells were stably transfected with the control vector or
knockdown construct for SIRT1 (SIRT1 KD) (Figure S1C). A
group of 15 mice were implanted with HMLER cells in the mam-
mary fat pad of nude mice (seven with control and eight with
HMLERSIRT1 KDcells), where they both grewmammary tumors
similar in size (Figure 1B). However, nude mice with SIRT1 KD
tumors had significantly reduced survival, with only 50% of
mice surviving until 8 weeks following the implantation of tumor
cells as compared to 86% survival in mice with wild-type tumors
(Figure 1C). In a second trial, 17 mice (eight control and nine
HMLER SIRT1 KD implanted cells) showed a similar pattern,
56% survival in mice with SIRT1 KD tumors and 100% survival
in mice with wild-type tumors 7.5 weeks following tumor implan-
tation (Figure 1D). Upon dissection, it was revealed in the first trial
that seven out of eight mice with SIRT1 KD tumors had multiple
metastases, in liver (50% of mice), lung (38% of mice), spleen
(13% of mice), and bone (13% of mice), while only one mouse
out of seven had a single liver metastasis after implantation of
wild-type tumor cells (Figure 1E). Metastasis burden analysis
showed a substantial portion of liver, lung, and spleen surface
covered with metastases in mice bearing SIRT1 KD tumors (Fig-
ures 1F and 1G). Histology of these organs showed the purely
differentiated phenotype characteristic of HMLER cells (Fig-Figure 1. The Role of SIRT1 in EMT of Breast Cancer Metastases
(A) Immunofluorescence staining of HMLER cells with E-cadherin, vimentin, and
DAPI staining of nuclei). Numbers in the bottom-right corners of images repres
number of cells per slide (n = 3 slides per group), shown as average ± SD, *p < 0
overexpressing SIRT1; siT1, HMLER cells with knockdown for SIRT1; Ctrl, contr
(B) Orthotopic mammary tumor weight following the termination of experiment.
(C and D) Survival of SCID mice up to 8 weeks (trial 1, left) and 7.5 weeks (trial 2, r
*p% 0.05 log-rank test versus HMLER control cells.
(E) Fraction of mice with metastases in different organs 8 weeks following the im
(F) Quantification of total organ metastasis burden (trial 1). Bars represent SD.
(G) Representative macroscopic images of mouse lung, liver, and spleen with
SCID mice.
(H) Hemalaun-eosin staining of mouse lung, liver, and spleen sections. M, metas
(I) Representative immunohistochemical staining of sections with anti-large T an
(J) Fraction of mice with metastases in different organs 7.5 weeks following the i
(K) Quantification of total organ metastasis burden (trial 2). Bars represent SD.
(L) Representative immunohistochemical staining of sections with anti-large T an
(M and N) HMLER and HMLER SIRT1 KD cells were induced to move and invade
were fixed, stained, and photographed. Representative photographs of transwel
counting the number of migrated cells. Columns, mean of triplicate assays; bars
(O) Meta-analysis of SIRT1 expression of 12 breast cancer clinical trials using
quadrants represent downregulation of SIRT1 and red upregulation. References
See also Figure S1.
Cure 1H). The origin of metastasis was additionally confirmed to
be HMLER cells with immunohistochemical staining of large
T antigen, used for transformation of HMEC to HMLER cells
(Figure 1I). In the second experiment, seven out of nine mice
with SIRT1 KD tumors had metastases, 56% in lung and
33% in liver (Figure 1J), with 31%–48% of organs covered with
metastases (Figure 1K). The HMLER origin of metastases was
confirmed by immunohistochemical staining of large T antigen
(Figure 1L) and scoring the GFP marker present in these cells
(Figure S1D). None of the mice with HMLER wild-type tumors
developed metastases in this experiment (Figures 1J and 1K).
SIRT1 levels in the knockdown remained low in metastases as
well as in primary tumors (Figure S1E). To determine migratory
and invasive abilities of cells more directly, we used Boyden
chamber assays. Whereas control cells were minimally motile
and invasive, SIRT1 KD cells showed a significant increase in
both motility and invasiveness through Matrigel-coated mem-
branes (Figures 1M and 1N). Taken together, these results indi-
cate that knocking down SIRT1 in breast cancer cells promotes
EMT, cancer cell invasiveness, metastases, and increased mor-
tality of nude mice.
To further confirm the effect of SIRT1 on breast cancer metas-
tases, we performed meta-analysis of SIRT1 expression in all
breast cancer clinical studies in the Oncomine human cancer
gene expression database, which includes 12 trials with 143
control and 1,181 breast cancer tissues (http://www.oncomine.
com). We used the cutoff value of p = 0.01 for significance of
any change in SIRT1 expression in any direction. Six out of 12
studies (nine out of 35 total comparisons) showed a significant
change in SIRT1 expression, and strikingly SIRT1 was downre-
gulated in all nine comparisons (fold change 1.216 to 4.822;
Figure 1O; Table S1).
Loss of SIRT1 Leads to Kidney Fibrosis via EMT
We next wished to test a possible role of SIRT1 in EMT in a
completely different context from tumor metastasis by usinga-SMA 8 days following the treatment with TGF-b 5 ng/ml (633 magnification,
ent percentage of E-cadherin, vimentin, and a-SMA-positive cells over total
.05, ANOVA Dunnett test, versus Ctrl treated with TGF-b; T1Tg, HMLER cells
ol HMLER cells.
ight) following the implantation of HMLER control and HMLER SIRT1 KD cells.
plantation of HMLER control cells and HMLER SIRT1 KD cells (trial 1).
visible metastatic nodules after implantation of HMLER SIRT1 KD cells in
tatic nodule; N, normal tissue.
tibody from the same set of organs. M, metastatic nodule; N, normal tissue.
mplantation of HMLER control cells and HMLER SIRT1 KD cells (trial 2).
tibody from the liver and lung (trial 2). M, metastatic nodule; N, normal tissue.
through Matrigel-coated transwell membranes. After 16 hr, the migrated cells
l membranes showing stained migrated cells. (M) Quantification of (N) done by
, SD; *p < 0.05, t test.
Oncomine database (cutoff for significant SIRT1 change was p = 0.01). Blue
are in Table S1.
ell Reports 3, 1175–1186, April 25, 2013 ª2013 The Authors 1177
Figure 2. The Role of SIRT1 in EMT of Kidney Epithelial Cells and Kidney Fibrosis In Vivo
(A) Immunofluorescent staining of HK-2 cells with E-cadherin, a-smooth muscle actin (a-SMA), and collagen type I 48 hr following the treatment with TGF-b
5 ng/ml (633 magnification, DAPI staining of nuclei). Numbers in the right bottom corners of images represent percentage of E-cadherin, a-SMA, or collagen-
type-I-positive cells over total number of cells per slide (n = 3 slides per group), shown as average ± SD, *p < 0.05, ANOVA Dunnett test versus Ctrl treated with
TGF-b; T1Tg, HK-2 cells overexpressing SIRT1; siT1, HK-2 cells with knockdown for SIRT1; Ctrl, control HK-2 cells.
(B) Changes of serum creatinine over time following AKI (n = 12 for each time point).
(C) Survival following the AKI. *p% 0.05 versus Ctrl KO, #p% 0.05 versus Ctrl Tg, log-rank test.
(D) Blood urea nitrogen (BUN) values over time (n = 12 for each time point).
(E) Masson’s trichrome staining showing mesenchymal tissue in blue and a-SMA immunofluorescent staining for myofibroblasts in red (magnification 203, n = 6
per group).
(F) Interstitial fibrosis score of Masson’s trichrome-stained kidney sections at 6 weeks following the AKI (n = 6 per group).
(G) Collagen content in kidneys 6 weeks following the AKI measured by Sircol assay (n = 6 per group).
(H) Masson’s trichrome staining of kidneys after 4 days of treatment with TGF-b 100 mg/kg/day intravenously (magnification 53).
(I) Interstitial fibrosis score of Masson’s trichrome-stained kidney slides from (H).
(J) Collagen content in kidneys after 4 days of treatment with TGF-b 100 mg/kg/day intravenously, as determined by Sircol collagen assay. *Significantly different
fromCtrl KO, #significantly different fromCtrl Tg, ANOVADunnett test, p% 0.05. Error bars represent SD. KSTG, kidney-specific transgenic mice; Ctrl Tg, control
for KSTG; KSKO, kidney-specific knockout mice; Ctrl KO, control for KSKO mice.
(legend continued on next page)
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kidney epithelial cells and a kidney injury model in mice express-
ing reduced or elevated levels of SIRT1 (Figure S2A).
Treatment of kidney epithelial HK-2 cells with TGF-b or aristo-
cholic acid, to mimic kidney injury, gave rise to cells with mesen-
chymal phenotypes, as shown by an increase in cells positive for
a-smooth muscle actin (a-SMA) and collagen type I (markers for
mesenchymal cells) and a decrease in cells positive for E-cad-
herin, an epithelial marker (Figures 2A and S2B). Overexpression
of SIRT1 in epithelial HK-2 cells led to a repression of EMT, as
seen by a reduction in a-SMA and collagen-positive cells. More-
over, preservation of the epithelial phenotype was confirmed by
the continued expression of E-cadherin after the treatments with
TGF-b or aristocholic acid (Figures 2A and S2B). Conversely,
loss of SIRT1 by siRNA in HK-2 kidney epithelial cells increased
the EMT, as assessed by an increase in a-SMA and collagen-
positive cells and a decrease in E-cadherin-positive cells (Fig-
ures 2A and S2B).
To test the effect of SIRT1 on kidney function in vivo, we
studied the acute kidney injury (AKI) model of ischemia reperfu-
sion in kidney-specific knockout mice (KSKO) and kidney-spe-
cific transgenic mice (KSTG) mice. KSKO mice eliminate SIRT1
from kidney collective tubular epithelial cells, while KSTG in-
crease SIRT1 expression in these same cells (Figures S2C–
S2E). At the baseline, KSTG and KSKO had comparable body
weight and levels of serum electrolytes (Figures S2F and S2G).
Serum creatinine values, representing kidney function, were
increased in KSKO mice before the AKI (Figure 2B), suggesting
the requirement of SIRT1 for maintenance of tubular epithelial
function even in the absence of injury. After clamping the renal
arteries to induce injury, the increase of the serum creatinine
was much more pronounced in the absence of SIRT1 from
kidney tubules (Figure 2B). There was an improvement in creat-
inine values in KSKO mice on day 4 following the AKI, since the
mice with the worst glomerular function had died by that time
(Figure 2C). KSTG showed better kidney function parameters
with significantly lower creatinine values as compared to the
control animals. Blood urea nitrogen (BUN) paralleled serum
creatinine measurements (Figure 2D). Most importantly, overex-
pression of SIRT1 in kidney tubules protected animals from
dying after AKI, while deletion exacerbated mortality (Figure 2C).
Histological examination of the injured kidneys demonstrated
destruction of the tubular basement membrane and disorienta-
tion of epithelial tubular cells following the AKI. These pheno-
types were significantly more pronounced in KSKO and reduced
in KSTG mice (Figures S2H and S2I).
Since aging impedes the recovery from AKI and predisposes
to irreversible damage of kidneys (Abrass et al., 1995), we
investigated the effect of SIRT1 on fibrosis in kidneys without
the injury and on progression of AKI to tubulointerstitial fibrosis
and development of chronic kidney damage (CKD) by following
the KSKO and KSTGmice for 6 weeks after the AKI. At baseline,(K) Percentage of a-SMA-positive cells in kidneys of SIRT1+/+ mice expressing t
(L) Percentage of cre-recombinase-positive cells out of a-SMA-positive cells in k
detected by flow cytometry.
(M) Quantitative RT-PCR analysis of cre-recombinase expression in sorted a-SMA
and KSKO mice.
Bars, SD, *p < 0.05 versus Ctrl, t test. See also Figure S2.
CKSKO mice had a minimal increase in kidney fibrosis (Fig-
ure S2J). After the AKI, KSKO mice had significantly worse
kidney function as detected by the increased serum creatinine
(Figure S2K) and BUN (Figure S2L), more kidney fibrosis (Fig-
ure 2F) as confirmed byMasson’s trichrome staining for connec-
tive tissue and a-SMA staining for myofibroblasts (Figure 2E) and
increased kidney collagen content (Figure 2G). In contrast, KSTG
showed improvement compared to the control mice subjected
to kidney injury. In summary, the elimination of SIRT1 predis-
poses kidneys to fibrosis and progression fromAKI to CKD,while
overexpression of SIRT1 in kidney tubules improves the recovery
after the AKI and slows the progression toward CKD.
Our findings above suggest that SIRT1 represses kidney
fibrosis. Since it is known that the TGF-b pathway induces
fibrosis (Ledbetter et al., 2000), we tested whether SIRT1 repres-
sion of TGF-b was sufficient to explain the observed repression
in fibrosis. We treated wild-type, KSKO, and KSTG mice with
100 mg/kg of TGF-b intravenously for 4 days. In mice treated
with TGF-b, we recapitulated the effects of SIRT1 seen after
AKI. Namely, KSTG mice showed less fibrosis on histology (Fig-
ures 2H and 2I) and less collagen (Figure 2J) in kidney tissues,
and KSKO mice showed more fibrosis and collagen after the
treatment with TGF-b. These results suggest that SIRT1 re-
presses kidney fibrosis by repressing the TGF-b pathway.
To address whether EMTwas likely to be involved in fibrosis in
wild-type or KSKO kidneys, we FACS sorted a-SMA-positive
cells after treatment with TGF-b to cause fibrosis, and found,
as expected, 4.8-fold more positive (fibrotic) cells in kidneys of
KSKO mice (Figure 2K). Since cre-recombinase expression in
KSKO mice is driven by the kidney epithelial collecting tubule-
specific Hoxb7cre promoter (Yu et al., 2002), we tested for
EMT by FACS sorting the a-SMA-positive cells and testing for
cre expression. Consistent with recent reports (Humphreys
et al., 2010), almost none of sorted a-SMA-positive cells had
cre recombinase (0.02%) in SIRT1+/+ mice expressing cre, after
the TGF-b treatment. In striking contrast, 35.7% of a-SMA-
positive cells in KSKO treated with TGF-b expressed cre recom-
binase (Figure 2L). Quantitative RT-PCR also demonstrated
vastly higher cre expression in a-SMA-positive cells of KSKO
compared to wild-type (Figure 2M). These findings suggest
that EMT is not the mechanism of kidney fibrosis in control
animals as recently reported (Humphreys et al., 2010). However,
EMT is induced at a very high frequency in fibrotic kidney tissue
in the absence of SIRT1.
SIRT1 Deacetylates Smad4 and Represses the Activity
of TGF-b Pathway on MMP7
Since MMP7 has been associated with aging and fibrosis in
kidneys (Chen et al., 2007), we determined the levels of this pro-
tein in the various mice after AKI. In KSTGmice, there was signif-
icantly less expression of MMP7 after AKI, while the expressionhe cre-recombinase (Ctrl) and KSKO mice detected by flow cytometry.
idneys of SIRT1+/+ mice expressing cre-recombinase (Ctrl) and KSKO mice as
-positive cells from kidneys ofSIRT1+/+mice expressing cre-recombinase (Ctrl)
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Figure 3. SIRT1 Represses the Activity of TGF-b Pathway on MMP7
(A) MMP7 fold change detected by quantitative RT-PCR in kidneys 6 days following the AKI (n = 6 per group).
(B) Immunohistochemistry showing localization of MMP7 around tubules in kidneys 6 days following AKI (Vecta-stain, 53 magnification).
(C) Immunofluorescent staining for collagen type IV for tubular basement membrane and DAPI for nuclei in kidney sections 6 days following AKI (203 magni-
fication). Numbers in the bottom-right corners of images represent percentage of collagen-IV-positive green area over total area (n = 3 slides per group), shown as
average ± SD. Arrows depict destruction of collagen IV in the basement membrane.
(D) Quantitative RT-PCR expression of TGF-b I and some of TGF-b target genes—Pitx2. Lefty and Afp—in kidneys 6 days following AKI.
(E) Luciferase activity of MMP7 promoter (660 to 280) in wild-type, SIRT1/ and SIRT1-overexpressing MEFs treated with TGF-b (2 ng/ml for 48 hr). Left,
vector control; right, shRNA Smad4.
(F) MMP7 immunofluorescent staining of kidney epithelial tubular HK-2 cells treated with TGF-b 5 ng/ml for 48 hr (633magnification, DAPI staining of nuclei). Bar
graph is quantification of MMP7 immunofluorescence intensity by ImageJ. In each of the four groups, three to four different fields were analyzed. *Significantly
different from Ctrl, ANOVA Dunnett test, p% 0.05. Error bars represent SD.
(G) Chromatin-immunoprecipitation on kidneys 6 days following the AKI with anti-Smad4 antibody or IgG. Different activity regions of the MMP7 promoter are
tested by quantitative RT-PCR using the appropriate primers (Table S2).
(legend continued on next page)
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of MMP7 was increased 5.7-fold in KSKO kidney (Figure 3A).
Immunohistochemistry revealed increased levels of MMP7 pro-
tein at the basement membrane of collecting tubules in KSKO
mice (Figure 3B). The increment of MMP7 in KSKO kidneys
correlated with increased destruction of collagen IV, a basement
membrane-specific target of MMP7, as shown by immunofluo-
rescent staining (Figure 3C). Conversely, there was less MMP7
protein and less basal membrane destruction in kidneys from
KSTG mice (Figures 3B and 3C). There were no significant
changes in the expression of MMP2 or MMP9 (Figure S3A).
Since TGF-b signaling is the most significant pathway leading
to EMT, cancer metastases, and fibrosis, we also analyzed the
effect of SIRT1 levels on the TGF-b pathway. The expression
of downstream genes involved in the TGF-b pathway was signif-
icantly increased in the absence of SIRT1 from kidney tubules
after injury, as confirmed by quantitative RT-PCR expression of
TGF-b pathway downstream targets Pitx2, Lefty, and Afp (Fig-
ure 3D). However, there was no significant change in TGF-b
expression itself among all groups subjected to kidney injury
(Figure 3D).
To address whether the SIRT1 regulation of MMP7 expression
was via the TGF-b pathway, we first monitored MMP7 expres-
sion in HK-2 kidney epithelial cells that either overexpressed or
had knocked down levels of SIRT1 (Figure S2A). Overexpression
of SIRT1 reduced the levels of TGF-b-induced MMP7, while
knockdown of SIRT1 increased levels (Figure 3F). To confirm
that SIRT1 regulated MMP7 via TGF-b signaling, we next con-
structed a luciferase reporter driven by a large fragment of
MMP7 upstream DNA (660 to 216) and tested it in wild-
type, SIRT1/, and SIRT1-overexpressing mouse embryonic
fibroblasts (MEFs). This reporter showed a strong regulation by
SIRT1, which was partially normalized by small hairpin RNA
(shRNA) to Smad4, the transcription factor that responds to
TGF-b signaling (Figures 3E and S3B).
The SIRT1 effects on TGF-b and MMP7 might occur via an
interaction between the TGF-b-activated transcription factor
Smad4 and a site in the MMP7 promoter. To test this idea,
we performed chromatin immunoprecipitation assay, which re-
vealed a direct interaction of Smad4, with a specific region of
MMP7 promoter 438 to 379, but not with other promoter re-
gions (Figures 3G and S3C). Critically, this interaction is greatly
enhanced in the SIRT1/ kidneys and reduced in kidneys
overexpressing SIRT1. To further validate the relevance of this
MMP7 promoter site, we constructed a luciferase reporter with
only the 438 to 379 region and tested it in MEFs. Luciferase
levels were activated by TGF-b, and activation was higher in
SIRT1/ MEFs and blunted in SIRT1-overexpressing MEFs
(Figure 3H). The increase in activity of this promoter in SIRT1/
MEFs was eliminated by treating cells with shRNA for Smad4.(H) Luciferase reporter assays of MEFs overexpressing SIRT1 (T1TG), lacking SI
driven by theMMP7 promoter region responsive to Smad4 (438 to379) and/o
as described in Experimental Procedures.
(I) Chromatin-immunoprecipitation on HMLER and HMLER T1KD cells with ant
promoter are tested by quantitative RT-PCR using the appropriate primers (Tabl
Ctrl Tg, control for SIRT1 kidney-specific transgenic mice; KSTG, kidney-specifi
KSKO, kidney-specific knockout mice. *Significantly different from Ctrl KO; #si
represent SD. See also Figure S3.
CWe confirmed the interaction between Smad4 and the MMP7
promoter by chromatin immunoprecipitation in HMLER T1KD
cells (Figure 3I). There was no direct interaction of SIRT1 and
the MMP7 promoter in HMLER cells (Figure 3I), suggesting
SIRT1 may function by deacetylating Smad4. We also used a
different assay for Smad4 activity—a Gal4 fusion to a Smad2/4
interacting motif from Fox H1 to recruit phosphorylated
Smad2-Smad4 complexes to a Gal4 binding site that drives
luciferase (Ross et al., 2006). Using this assay in the MEFs, there
was again more activation of Smad2-Smad4 complex in the
absence of SIRT1 and less activation in cells overexpressing
SIRT1 (Figures S3D and S3E).
To test whether SIRT1 deacetylates Smad4, we immunopre-
cipitated Smad4 and also Smad2 from mouse kidneys and
probed western blots with antibodies to the Smad proteins or
acetyl lysine (Figure 4A). This experiment showed a clear in-
crease in acetylation of Smad4 but not Smad2 in the KSKO
kidneys. To investigate the effect of aging on the Smad4
pathway in wild-type kidneys, we tested the levels of SIRT1
protein and Smad4 acetylation in kidneys at different ages.
Interestingly, there was a decrease in SIRT1 levels in kidneys
from 2-year-old mice as compared to young mice at 3 months
of age (Figure 4B). Moreover, there was a corresponding in-
crease in Smad4 acetylation in aged kidneys (Figure 4B). We
also observed an increase in acetylation of Smad4 in SIRT1 KD
HMLER cells (Figure 4C). Finally, SIRT1 and Smad4 were shown
to interact at endogenous level in HMLER cells by coimmunopre-
cipitation (Figure S3F).
Furthermore, MMP7 protein levels were elevated in SIRT1
KD HMLER cells (Figure 4D). Since MMP7 cleaves E-cadherin
from the cell surface (Noe¨ et al., 2001; Zheng et al., 2009), we
tested the effect of SIRT1 on E-cadherin in HMLER cells.
SIRT1 KD HMLER cells showed modestly less E-cadherin on
western blot analysis. This effect was blunted by the reduction
of MMP7 levels, suggesting that SIRT1 KD exerts its effect on
E-cadherin via MMP7 (Figure 4D). Notably, TGF-b reduced
E-cadherin in both, wild-type and SIRT1 KD HMLER cells, but
to a much greater extent in SIRT1 KD cells, and this too was
blunted by shRNA for MMP7 (Figure 4D).
b-catenin is associated with the E-cadherin cytoplasmic tail,
and loss of E-cadherin leads to translocation of b-catenin from
adheren junctions to the nucleus (Onder et al., 2008). As SIRT1
KD reduces E-cadherin levels in HMLER cells, we investigated
whether this induced a change in the cellular localization of
b-catenin upon TGF-b addition. Indeed, SIRT1 KD led to trans-
location of b-catenin from the cell junctions (characteristic of
epithelial cells) to nuclei (characteristic of mesenchymal cells,
Kalluri and Weinberg, 2009) upon addition of TGF-b (Figures
4E and S4).RT1 (T1/), or controls (Ctrl). Cells were transfected with luciferase reporter
r Smad4 shRNA, and were incubated with TGF-b 2 ng/ml for 48 hr and assayed
i-Smad4, anti-SIRT1 antibody, or IgG. Different activity regions of the MMP7
e S2).
c transgenic mice; Ctrl KO, control for SIRT1 kidney-specific knockout mice;
gnificantly different from Ctrl Tg, ANOVA Dunnett test, p % 0.05. Error bars
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Figure 4. SIRT1 Deacteylates Smad4 Repressing the Activity of MMP7 on E-Cadherin Cleavage and b-Catenin Cellular Translocation
(A) Western blot of kidney samples 6 days following the AKI. Kidney samples were immunoprecipitated with Smad4 and Smad2 antibody or immunoglobulin G
(IgG), and the blots were probed with acetyl-lysine (AcLys), Smad2, and Smad4 antibodies.
(B) Western blot of kidneys from 2 year (old) and 3month (young) animals, probed with SIRT1 and immunoprecipitated with Smad4 or IgG and probed with acetyl-
lysine antibody. Numbers below lanes are quantification by ImageJ, shown as a fold change in band intensity normalized to young kidneys.
(C) Western blot of HMLER cells immunoprecipitated with antibody or immunoglobulin G (IgG). Blots were probed with acetyl-lysine (AcLys) and Smad4
antibodies.
(D)Western blots of HMLER control and HMLERSIRT1 KD cells treatedwith TFG-b 5 ng/ml for 48 hr and transfectedwith shMMP7, as indicated. Blot was probed
with E-cadherin, MMP-7, and tubulin antibodies. Numbers below lanes are quantification by ImageJ, shown as a fold change in band intensity normalized to
HMLER cells without TGF-b treatment and shMMP7 transfection.
(E) Immunofluorescent staining for b-catenin of HMLER and HMLER SIRT1 KD cells treated with TGF-b (5 ng/ml), as indicated. The images show a slice through
the nuclei of cells analyzed by confocal microscopy. Analysis of images stacks confirmed nuclear localization in the SIRT1 knockdown HMLER cells but not
control HMLER cells.
See also Figure S4.Finally, we do not believe that the effect of SIRT1 on metas-
tasis occurs via p53. HMLER cells are transfected with SV40,
and the expressed T antigen is known to inactivate p53. Indeed,
doxycyline was not able to induce p21, a p53 target, in HMLER
cells, while serving as a potent inducer in 143b control cells
(Figure S5).
DISCUSSION
Our results show that reduction of SIRT1 promotesmetastasis of
breast epithelial cells in an orthotopic model of breast cancer
and promotes EMT and cell motility in these cells in vitro. Further,
EMT could be induced in both breast epithelial and kidney
epithelial cells in vitro, and this was also repressed by SIRT1.1182 Cell Reports 3, 1175–1186, April 25, 2013 ª2013 The AuthorsThese effects were associated with the hyperactivation of
TGF-b and hyperacetylation of Smad4 in the absence of
SIRT1, leading to an increase in expression of MMP7, which
we demonstrate is a Smad4 target. We suggest that the absence
of SIRT1 leads to MMP7 hyperexpression and degradation of
E-cadherin from the cell surface, thereby releasing b-catenin
from the cadherin junctions to the nucleus, which is the charac-
teristic of mesenchymal cells (Figures 5A and 5B).
The literature suggests that the role of SIRT1 in cancer may
depend on the tumor type. SIRT1 has been shown to protect
against gut carcinomas in APCmin mice (Firestein et al., 2008),
as well as tumorigenesis in p53+/mice (Wang et al., 2008; Vaziri
et al., 2001). However, SIRT1 was associated with malignancy in
prostate cancer and chronic myelogenous leukemia (Byles et al.,
Figure 5. Schematic Representation of
SIRT1 Effects on EMT
(A and B) Without SIRT1 (A) and with SIRT1 (B).2012; Li et al., 2012). In prostate cancer, SIRT1 enhanced cell
migration and metastasis after PC3 cancer cell tail injections
by cooperating with EMT transcription factor ZEB1 to suppress
E-cadherin transcription (Byles et al., 2012). The SIRT1 activator
compound 1720 was shown to increase lung metastasis of
implanted breast cancer cells, but EMT as a possiblemechanism
was not addressed (Suzuki et al., 2012). In normal mouse mam-
mary epithelial cells, miR-200a negatively regulated SIRT1
expression and reduced EMT (Eades et al., 2011). However, an
opposite role in cancer metastasis was indicated by the demon-
stration that miR-520c and miR-373 suppressed SIRT1 transla-
tion leading to increased expression of MMP9 and enhanced
cell migration of fibrosarcoma cells (Liu and Wilson, 2012). To
further confirm our data in animal studies, we performed the
meta-analysis of human breast cancer trials and have shown
that SIRT1 is downregulated in human invasive breast cancers.
Because of these seemingly conflicting data on SIRT1 in
cancer, we employed a radically different model to follow up
the cancer studies—fibrosis following kidney injury. Renal
fibrosis after injury was mitigated in mice overexpressing
SIRT1 in the kidney tubular epithelial cells and exacerbated in
mice with SIRT1 knocked out in those cells. This repression of
fibrosis was due to repression of TGF-b signaling. For years it
was believed that EMT is a major mechanism of renal fibrosis.
However, a more recent study using fate tracing showed that
epithelial cells do not give rise to interstitial myofibroblasts in
wild-type mice following injury (Humphreys et al., 2010). We
were able to confirm that EMT did not occur in fibrotic tissue of
wild-type animals after injury. However, in the absence of
SIRT1, 36%of interstitial myofibroblasts expressed the epithelial
marker Hoxb7cre, suggesting their epithelial origin.
We also found long-term protective effects of SIRT1 after AKI
in the progression to chronic disease. Previous studies had
demonstrated SIRT1 protection using acute models of injury.
For example, transgenic mice were protected against apoptosis
of kidney tubular epithelium (Hasegawa et al., 2010), but
SIRT1+/ heterozygotes were more susceptible to damage of
medullar interstitial cells (He et al., 2010). In addition, calorie
restriction protected against hypoxic AKI by increasing SIRT1
levels (Kume et al., 2010), and pharmacological activation of
SIRT1 was also protective (Hasegawa et al., 2010; Lee et al.,
2010; Li et al., 2010a; Funk et al., 2010).
SIRT1 represses the TGF-b signaling pathway important in
EMT. TGF-b promotes differentiation and activation of myofibro-
blasts, which trigger scar and fibrous tissue formation and facil-
itate cancer progression and metastasis (Wendt et al., 2009).
Further, TGF-b stimulation of EMT has been associated withCell Reports 3, 1175–118the selection and expansion of breast
cancer stem cells (Mani et al., 2008;Morel
et al., 2008; Ben-Porath et al., 2008). Our
results show that SIRT1 deacetylates and
represses Smad4 in the TGF-b pathway,which lowers the expression of target genes. A previous study
showed that SIRT1 deacetylated the negative regulator of
TGF-b signaling, Smad7, to destabilize the protein in amesangial
kidney cell line (Kume et al., 2007). Were this to occur in the
tubular epithelial cells in vivo, it might be expected to counteract
the effect of SIRT1 on TGF-b signaling due to repression of
Smad4. Our data indicate that the net effect of SIRT1 is to
repress the output TGF-b pathway in tubular epithelial cells, sug-
gesting that effects of this sirtuin on Smad7 are at best minor in
these cells.
We also show that TGF-b regulates MMP7 expression, which
is hyperexpressed when Smad4 is hyperacetylated in the
absence of SIRT1. Further supporting the relationship between
Smad4 and MMP7, MMP7 becomes dispensable for invasion
in Smad4-deficient adenocarcinomas (Kitamura et al., 2009).
MMP7 releases 80 kDa ectodomain fragment of E-cadherin
(Noe¨ et al., 2001), and we show a reduction of E-cadherin by
MMP7 cells lacking SIRT1. Since disruption of E-cadherin by
MMPs can mediate EMT (Zheng et al., 2009), metastasis (Onder
et al., 2008), and cause nuclear translocation of b-catenin (Zheng
et al., 2009; Onder et al., 2008), SIRT1 also leads to repression of
a second pathway involved in EMT, Wnt signaling.
Interestingly, MMP7 levels increase in aging breast epithelial
cells, which may contribute to age-associated breast cancer
development (Chaturvedi and Hass, 2011). MMP7 levels also
increase in tubular epithelial cells with age (Chen et al., 2007).
As we show a decrease in SIRT1 levels and a corresponding
increase in Smad4 acetylation in aged kidneys, it is interesting
to speculate that the effect of MMP7 may be due to loss of
SIRT1 activity in aging tissues.
In conclusion, SIRT1 reduces EMT in cancer and fibrosis
by deacteylating Smad4 and repressing the effect of TGF-b
signaling on MMP7. Consequently, less E-cadherin is cleaved
from the cell surface and b-catenin remains bound to E-cadherin
at the cell-cell junctions. These findings suggest that SIRT1 may
be a target for prevention or possibly treatment of cancer metas-
tasis and organ fibrosis.
EXPERIMENTAL PROCEDURES
Mouse Strains
Severe combined immunodeficiency mice were purchased from Charles River
Laboratories. All other mice were in congenic C57Bl/6 background. KSKO
mice were generated by crossing SIRT1 allele containing a floxed exon 4
(Cheng et al., 2003) with Cre-expressing mice driven by the kidney epithelial
collecting tubule-specific Hoxb7cre promoter (Jackson Laboratory). KSTG
mice were generated by crossing SIRT1 loxP-flanked mice (Firestein et al.,
2008) with mice having Hoxb7cre promoter. Ctrl Tg mice had no loxP locus6, April 25, 2013 ª2013 The Authors 1183
nor cre recombinase. All mice were housed at 25C and 12:12 hr light/dark
cycle. All experiments were performed in accordance to Massachusetts
Institute of Technology guidelines and regulations and were approved by
Committee on Animal Care.
Cells and Treatment
Immortalized tumorigenic primary human breast epithelial cells, HMLER cells
(courtesy by R.A. Weinberg, Whitehead Institute), were maintained as
described (Elenbaas et al., 2001). The SIRT1+/+ and SIRT1/ MEFs have
been described (Lin et al., 2000). HK-2 cells were from ATCC. Cells were
treated with 5 ng/ml TGF-b (Invitrogen) or aristocholic acid (Sigma) every other
day for 2–8 days (Yang et al., 2010; Yu et al., 2002).
Plasmids and Cell Transfections
Stable cells were generated using lentivirus or retrovirus. The plasmids ex-
pressing mSIRT1 and PRRL-GFP vectors were purchased from Addgene,
Smad4-shRNA, and pSM2 vector from Open Biosystems. siRNA-SIRT1
plasmid has been previously described (Picard et al., 2004). Lentiviral vectors
were made by pcr subcloning cDNA and ligating into pENTR-D-TOPO
(Invitrogen). pENTR-D-TOPO vectors were sequenced and then the cDNA
was transferred to pLenti4-TO-V5-DEST (Invitrogen) through recombination.
Cells were then virally infected. Transient transfections were performed by
using Fugene transfection reagent (Roche).
In Vivo Tumorigenesis and Metastasis Model
Severe combined immunodeficiency (SCID) mice (Charles River Laboratories)
were used in these studies, and all the protocols were approved by the
Massachusetts Institute of Technology Committee on Animal Care. Mice
were anesthetized with isoflurane. Five million cells in PBS, diluted 1:2 with
Matrigel (Beckton Dickinson), were injected into one mammary gland per
female (Onder et al., 2008). Animals were sacrificed 7.5 or 8 weeks postinjec-
tion (depending when the primary tumors reached 2 cm in diameter), or sooner
if they became moribund.
Meta-Analysis of Breast Cancer Clinical Trial
We performed meta-analysis of SIRT1 expression in Oncomine database of
breast cancers (http://www.oncomine.com). The analysis included 12 trials
with 143 control and 1181 breast cancer tissues (Table S1). These 12 trials
had 35 comparisons. We used the cutoff value of p = 0.01 for significance of
SIRT1 expression change in any direction.
Acute Kidney Injury Model
Four-month-old mice (n = 12 per group) were subjected to ischemia-reperfu-
sion model of AKI by clamping both renal pedicles for 30 min with vascular
clips (Roboz) (Yang et al., 2010). Blood was collected throughout the experi-
ment and kidneys at the end. Mice were sacrificed 6 days and 6 weeks
following the AKI and experiment was repeated twice.
TGF-b Injections
TGF-b 100 mg/kg/day was injected intravenously to six mice/group for 4 days
to induce kidney fibrosis. Mice were sacrificed on day 5 and kidneys were
collected for analyses. The experiment was repeated twice.
Renal Function
Serum level of creatinine was measured by alkaline picrate, BUN by urease
and potassium by ion-selective electrode method (Antech Diagnostics).
Histology, Histomorphometry, and Immunohistochemistry
Metastasis, kidney, bone, and adipose tissue histology was examined on
formalin-fixed, paraffin-embedded sections 3 mm thick stained by hematoxy-
lin-eosin andMasson’s trichrome for kidneys (six sections/kidney). The degree
of interstitial fibrosis was scored semiqantitatively on a 0–4 scale (0, no lesion;
1, <25%; 2, >25%–50%; 3, >50%–75%; 4, >75% of parenchyma affected by
the lesion) (Yang et al., 2010). The collagen content of kidneys was quantified
with the Sercol soluble collagen assay kit (Biocolor).
Vectastain kit (Vector Laboratories) and MM7 (Abcam) and large SV40 T
antigen (Santa Cruz) antibodies were used to perform MMP7 staining of three1184 Cell Reports 3, 1175–1186, April 25, 2013 ª2013 The Authorsconsecutive kidney sections and large SV40 T antigen, used to transform
HMLE cells, staining of tumor metastasis.
Immunofluorescent Staining
Kidney sections were labeled with antibody to a-SMA (Abcam) and collagen
type IV. HMLER cells and HK-2 cells on coverslips were labeled with anti-
bodies to E-cadherin (BD Transduction Laboratories), a-SMA, collagen type
I and type IV (Abcam), vimentin (Abcam), and MMP7. HMLER cells were
labeled with b-catenin antibody. The slides were exposed to Alexa Fluor
488, 568, and 594 anti-rabbit and anti-mouse secondary antibodies
(Invitrogen). The staining was examined with fluorescence microscope (Zeiss
AxioImager.M1). HMLER cells labeled with GFP were detected macroscopi-
cally after forming metastasis at necroscopy when organs were examined
under a Leica MZ 12 fluorescence dissection microscope.
Western Blotting and Immunoprecipitation
Organs and cells were homogenized in RIPA buffer including Complete Prote-
ase Inhibitor (Roche). Protein (100 mg) was loaded onto SDS-PAGE gels and
immunoblotted with anti-SIRT1 (Upstate), Smad2 (Abcam), Smad4 (Abcam),
E-cadherin (Cell Signaling), MMP7 (Abcam), Acetyl-Lysine (Santa Cruz
Biotechnology), and tubulin (Abcam) antibodies.
The immunoprecipitations were carried out by using Pierce Direct IP Kit
(Thermo Scientific). To determine Smad2 and Smad4 acetylation, anti-
Smad2, anti-Smad4, or normal rabbit serum were coupled to agarose beads,
and then control, KSKO, KSTG kidney samples, HMLER control, and HMLER
SIRT1 KD cells were incubated with the beads. The eluate was blotted with
anti-Smad2, anti-Smad4, and anti-Acetyl-Lys antibodies.
Flow Cytometric Analysis and Sorting
Cell suspension from kidneys of control mice with cre-recombinase and
KSKO mice after 4 days of treatment with TGF-b 100 mg/kg/day was pre-
pared as described in Kitamoto et al. (2009). Following erythrocyte lysis,
cells were resuspended in FACS buffer. Kidney cells were labeled using
anti-a-SMA and anti-cre-recombinase primary antibodies and Alexa Fluor
488 and Alexa Fluor 647 secondary antibodies, counted by a FACSCalibur
Flow Cytometer (BD Biosciences) and analyzed using FlowJo software
(Ashland, OR). a-SMA-positive cells were sorted using FACSAria I (BD
Biosciences).
RNA Isolation and Analysis
Total RNA from mouse kidneys and HMLER cells was isolated by using Trizol
(QIAGEN). cDNA was synthesized from total RNA by SuperScript III reverse
transcriptase (Invitrogen) with random primers. The cDNA was then subjected
to real-time quantitative RT-PCR analysis with gene-specific primers in the
presence of CYBR green (Bio-Rad). Relative abundance of mRNAwas normal-
ized to rpl19.
Chromatin Immunoprecipitation Analysis
Chromatin immunoprecipitation analysis from kidneys and HMLER cells was
performed with Magna Chip kit (Millipore) by using Smad4 antibody (Abcam)
and immunoglobulin (Ig) G. The primer sequences are in Table S2.
Luciferase Assay
Transcription of Smad2-Smad4 was detected by transfecting MEFs with
FM-SIM plasmid comprising of Smad-interacting motif (SIM) and Fast/
FoxH1 motif (FM), which interacts with phospho-Smad2, fused to the
Gal4 DNA-binding domain (Figure S5A) (Ross et al., 2006; courtesy of
C. Hill, Cancer Research, UK). The MMP7 promoter region responsive to
Smad4 (438 to 379) and a larger DNA promoter fragment (660
to 216) were cloned into pGL3-basic vector luciferase plasmid (Addgene)
by using Sac1 and Xhol restriction endonucleases (New England BioLabs).
Cells were cotransfected with MMP7 promoter-luciferase reporter and
pRL-TK (Renilla luciferase; Promega) and treated with TGF-b 2 ng/ml for
48 hr. Luciferase activity was measured by Dual-Luciferase Reporter Assay
System (Promega). The firefly luciferase activity was normalized to Renilla.
The experiments were performed in triplicates and were repeated three
times.
Statistical Analysis
The analyses were performed using ANOVA Dunnett test, except for survival,
where log-rank test was used. Differences were considered significant if
p < 0.05.
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